Publication Type: Peer-Reviewed
-
Assessment of Plasma Proteomics Biomarker’s Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial
-
Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
-
A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
-
Erlotinib Plus Either Pazopanib or Placebo in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: A Randomized, Placebo-Controlled Phase 2 Trial With Correlated Serum Proteomic Signatures
-
The serum-based VeriStrat test is associated with proinflammatory reactants and clinical outcomes in non-small cell lung cancer patients
-
Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy
-
A Serum Protein Signature Associated with Outcome After Anti-PD1 Therapy in Metastatic Melanoma
-
Tumor-Associated Autoantibodies: Re-Optimization of Nodify CDT Diagnostic Performance and its Application to Indeterminate Pulmonary Nodules
-
Development and Clinical Utility of a Blood-Based Test Service for the Rapid Identification of Actionable Mutations in Non-Small Cell Lung Carcinoma.
-
An Integrated Risk Predictor for Pulmonary Nodules